Antiviral Drugs Market size was estimated at $55,102.8 Million in 2019 and is expected to reach $46,820.5 Million by 2027, growing at a CAGR of -2.3% during the forecast period of 2020 to 2027.
Antiviral drugs are meant to reduce the ability of flu viruses in the body to reproduce and spread further. With its proper consumption, the flu symptoms and duration is reduced in healthy adults and kids. The severity of flu is reduced substantially if these drugs are taken as per doctor’s advice. These drugs destroy viral infection the body and also help to build resistance against such viruses in the coming few months. Relapse is common in virus and flu hence proper prescribed routine of the antiviral drug is essential to curb further growth. The viruses these drugs can deal with are – human immunodeficiency virus, herpes, influenza, hepatitis and more.
Antiviral Drugs Market Growth Factors
The antiviral drugs market is heading towards growth due to increasing cases of HIV majorly. Infections of the respiratory syncytial virus, hepatitis and influenza are also slated to grow in number in the days to come. The only major restraining force for growth is the fact that awareness is being spread globally regarding the availability of vaccines for these viruses. Vaccines will inversely impact the market for antiviral drugs. There are branded and generic categories of these drugs available in the market. The recent global pandemic of COVID-19, which also happens to be a virus led to disease, has surged the demand for antiviral drugs sky high. Unless a vaccine comes out for the disease, the drug market will keep growing and double its CAGR for the period easily. The patient pool suffering from viral infections is increasing, and hence 6% of growth in market cap is expected by the year 2025. Cipla Inc., AbbVie Inc. And Gilead Sciences Inc are some of the key players of the market.
Antiviral Drugs Market Segmentation
Antiviral Drugs Market Country Analysis
The global antiviral drugs market is expected to grow tremendously in the next 7 years to reach $75.33 billion. The growth in the market is driven by the increasing prevalence of viral diseases such as hepatitis, HIV, influenza and respiratory syncytial virus that take antiviral drugs to treat. North America dominates the antiviral drugs market due to increased awareness of viral diseases and availability of a better healthcare infrastructure. Asia-Pacific, particularly in the South Asian countries is anticipated to record significant growth. Companies that are propelling this growth include Johnson & Johnson Services Inc., GlaxoSmithKline Plc., Hoffmann-La Roche AG, Gilead Sciences, Aurobindo Pharma and Dr. Reddy’s Laboratories Ltd among others.
Antiviral Drugs Market Share and Competition
Key companies operating in this industry are: Johnson & Johnson, Merck & Co. Inc., Gilead Sciences Inc., Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Abbott Laboratories, Novartis International AG, Astra Zeneca AB, Cipla Inc.
NanoViricides Inc., a leader in providing effective antiviral therapies through its platform, has announced on 30 June 2020, that it has been added to the Russell Microcap Index. “We believe inclusion in the Russell Microcap index is a consequence of the significant progress we have made recently.”, informed Anil R. Diwan, President and Executive Chairman of NanoViricide.
Zydus Cadila, a multinational drug firm, has announced the approval of its new antiviral drug Atazanavir from the United States Food and Drug Administration (USFDA), on 5 June 2020. The company will produce the drug at the manufacturing facility SEZ in Ahmedabad. The antiviral drug, Atazanavir, has been engineered to cure Human Immunodeficiency Virus (HIV-1) Infection in addition to many other retroviral drugs. The company also informed that it has 291 of approved drugs and has filed over 300 more Abbreviated New Drug Applications (ANDAs) in the last quarter.
Two anti-viral drug companies have hit the drugs market in India by the approval of new drugs for the novel Covid-19. Glenmark has announced the approval of its new drug Fabiflu, on 23 June 2020. Followed by this approval, another pharmaceutical drug company, Gilead, has also got an approval for ‘Covifor’, another drug for the treatment of Corona Virus.
Report Highlights
• Historical data available (as per request)
• Estimation/projections/forecast for revenue and unit sales (2020 – 2027)
• Data breakdown for every market segment (2020 – 2027)
• Gross margin and profitability analysis of companies
• Price analysis of each product type
• Business trend and expansion analysis
• Import and export analysis
• Competition analysis/market share
• Supply chain analysis
• Client list and case studies
• Market entry strategy
Industry Segmentation and Revenue Breakdown
Mechanism of Action Analysis (Revenue, USD Million, 2020 - 2027)
• Reverse transcriptase inhibitors, polymerase inhibitors
• Protease inhibitors
• Others
Application Analysis (Revenue, USD Million, 2020 - 2027)
• HIV/AIDS
• Herpes
• Hepatitis
• Influenza
• Others
Region Analysis (Revenue, USD Million, 2020 - 2027)
• United States
• Canada
• Mexico
• France
• Germany
• Italy
• Spain
• United Kingdom
• Russia
• China
• India
• Philippines
• Malaysia
• Australia
• Austria
• South Korea
• Middle East
• Japan
• Africa
• Rest of World
Antiviral Drugs Market Companies
• Johnson & Johnson
• Merck & Co. Inc.
• Gilead Sciences Inc.
• Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc
• Abbott Laboratories
• Novartis International AG
• Astra Zeneca AB
• Cipla Inc.
Available Versions:-
United States Antiviral Drugs Market Industry Research Report
Europe Antiviral Drugs Market Industry Research Report
Asia Pacific Antiviral Drugs Market Industry Research Report
